Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13863924 | 0.89 | MEN1 (0.73) | TRPV1MEN1KMT2ABRAF | |
| SCHEMBL4433389 | 0.89 | TRPV1 (0.82) | TRPV1MEN1KMT2AMCHR1HTR2C | |
| SCHEMBL13998408 | 0.88 | TRPV1 (0.59) | TRPV1MEN1KMT2AMCHR1 | |
| SCHEMBL4433782 | 0.87 | TRPV1 (1.00) | TRPV1MEN1KMT2AMCHR1HTR2C | |
| SCHEMBL4425107 | 0.86 | TRPV1 (0.82) | TRPV1MEN1KMT2AMCHR1HTR2C | |
| SCHEMBL4430162 | 0.84 | TRPV1 (0.75) | TRPV1MEN1KMT2AMCHR1HTR2C | |
| SCHEMBL6363197 | 0.83 | MEN1 (0.64) | TRPV1MEN1KMT2ABRAF | |
| SCHEMBL4427373 | 0.82 | TRPV1 (0.78) | TRPV1MEN1KMT2AMCHR1HTR2C | |
| SCHEMBL4433847 | 0.80 | MEN1 (0.73) | TRPV1MEN1KMT2A | |
| SCHEMBL5934468 | 0.80 | TRPV1 (0.71) | TRPV1PTPN1PTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TRPV1 1/4885MEN1 3527/4885KMT2A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.